s 22(1) [redacted]

From: [redacted]
Sent: Tuesday, 25 July 2017 12:53 PM
To: DL TGA Branch Heads; DL MMDR Project Coordinators Forum; DL MMDR Change Management Leads
Subject: ERIC Minutes of 30 June 2017 [DLM=For-Official-Use-Only]
Attachments: [D17-550183] ERIC meeting outcomes - ratified - 30 June 2017.DOCX; [D17-550183] ERIC meeting outcomes - ratified - 30 June 2017.tr5

Follow Up Flag: Follow up
Flag Status: Flagged

Dear Branch Heads, Project Coordinators and Change Management Leads

Following the ERIC meeting of 14 July 2017 please find attached the ratified Minutes from the ERIC meeting of 30 June

The Minutes will also be uploaded to Sharepoint.

Kind Regards
[redacted]

[redacted]
Director
Reform Coordination and Support
Regulatory Services and Improvement Branch

Phone: [redacted]
Email: [redacted]

Therapeutic Goods Administration
Department of Health
PO Box 100
Woden ACT 2606 Australia
www.tga.gov.au

Australian Government

Department of Health

Expert Review Implementation Committee (ERIC)

Minutes of the Meeting of 30 June 2017

9.00am, Executive Boardroom

Member participants

s 22(1) [redacted]

Apologies

Nil

Attendees

s 22(1) [redacted]

Pages 3-7 inclusive exempt in full under section 22(1) of the FOI Act



8. Consultation analysis – Options for the future regulation of 'low risk' products

The ERIC was provided with the preliminary analysis of submissions to the public consultation 'Options for the future regulation of 'low risk' products' and the proposed next steps for this project.

The public consultation paper was published on the TGA website for six weeks (31 March – 12 May). In addition, key stakeholders were also specifically invited to comment. These stakeholders include peak industry bodies and health professional interest groups. A total of 1028 submissions were received, including 65 submissions from organisations. A number of submissions commented on the potential reforms to homoeopathic products.

The ERIC paper included:

- a table of organisations that provided a submission (with key organisations highlighted);
- a tally of responses by option for each 'low risk' product type; and
- a summary of key stakeholder submissions.

In many cases the options proposed for the future regulation of 'low risk' products were not mutually exclusive and several options could be implemented simultaneously for a particular product type. Despite this, many stakeholders simply indicated support for one option. Other than for homeopathy, there was reasonable consensus between professional healthcare associations and sponsors/manufacturers of the various product types.

The next steps for the project are:

- notifying the Minister of the consultation outcomes in late July 2017;

- publishing the consultation submissions and a brief response on the TGA website (subject to the Minister's clearance); and
- undertaking further internal consultation to develop specific policy proposals for ERIC for endorsement in late July/August, prior to seeking Ministerial approval in August/September. It is possible that some of the more straightforward and/or less contentious policy proposals will be ready for consideration prior to this, subject to further internal discussions.

ERIC:

- noted the summary of public consultation; and
- noted the next steps for "Options for the future regulation of 'low risk' products".

[redacted]